(Q40419010)

20 September 2017

title

Recruitment prior to ovarian stimulation: ways of improving follicular recruitment (English)

1 reference

20 September 2017

Richard Fleming

1

1 reference

20 September 2017

publication date

1 June 2005

1 reference

Reproductive BioMedicine Online

20 September 2017

published in

1 reference

20 September 2017

volume

10 Suppl 3

1 reference

20 September 2017

page(s)

55-59

1 reference

Factors regulating the growth of the preovulatory follicle in the sheep and human

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960391-X

7 January 2021

Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960391-X

7 January 2021

Follicle dynamics during ovarian ageing.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960391-X

7 January 2021

Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960391-X

7 January 2021

Premenstrual administration of gonadotropin-releasing hormone antagonist coordinates early antral follicle sizes and sets up the basis for an innovative concept of controlled ovarian hyperstimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960391-X

7 January 2021

Monitoring during gonadotrophin-releasing hormone antagonist protocols

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960391-X

7 January 2021

Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960391-X

7 January 2021

Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960391-X

7 January 2021

Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960391-X

7 January 2021

Primary amenorrhoea and infertility due to a mutation in the beta-subunit of follicle-stimulating hormone

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960391-X

7 January 2021

Oocyte-expressed genes affecting ovulation rate

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960391-X

7 January 2021

Apoptosis as a function of ovarian reserve in women undergoing in vitro fertilization

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960391-X

7 January 2021

Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960391-X

7 January 2021

Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960391-X

7 January 2021

Formation and early development of follicles in the polycystic ovary

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960391-X

7 January 2021

Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960391-X

7 January 2021

10.1016/S1472-6483(11)60391-X

Identifiers

DOI

1 reference

20 September 2017

1 reference